Malaria Diagnostics Market by Technology (Microscopy, Rapid Diagnostic Tests, Molecular Diagnostic Tests), End-user (Hospitals, Diagnostic Centers, Research Institutes), & Region for 2024-2031

Malaria Diagnostics Market Valuation – 2024-2031

The global malaria diagnostics market is propelled upward by technological advancements in diagnostic techniques. According to an analyst from Verified Market Research, the market valuation is estimated to reach USD 1295.97 Million by 2031, which is compared to its 2024 valuation of USD 826.61 Million.

The rapid expansion of the malaria diagnostics market is primarily driven by increasing awareness about early disease detection, rising investments in healthcare infrastructure in developing regions, and growing support from international health organizations. The market is projected to grow at a CAGR of 5.75% from 2024 to 2031.

To Get Detailed Analysis: Download Report PDF

Malaria Diagnostics Market: Definition/Overview

Malaria diagnostics are defined as tools and technologies that are utilized for the detection and confirmation of malaria parasites in human blood. It should be understood that accurate diagnosis is considered crucial for effective treatment and disease management. Various diagnostic methods are employed, ranging from traditional microscopy to advanced molecular techniques.

Furthermore, it must be noted that early and accurate diagnosis is emphasized as critical for preventing severe illness and reducing transmission. The global burden of malaria is addressed through improved diagnostic capabilities, which are integrated into healthcare systems worldwide.

What's inside a VMR
industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

>>> Ask For Discount @ – https://www.verifiedmarketresearch.com/ask-for-discount/?rid=39428

What Factors Are Identified as Growth Drivers in the Malaria Diagnostics Market?

The increased global incidence of malaria is a major driver of the malaria diagnostics market. According to the World Health Organization (WHO), there were an expected 247 million malaria cases worldwide in 2021, with 619,000 fatalities. The growing number of cases emphasizes the critical need for efficient diagnostic techniques to manage and control malaria.
The introduction of rapid diagnostic tests (RDTs) and polymerase chain reaction (PCR) techniques has improved malaria detection. The WHO claimed that the availability of RDTs has expanded dramatically, with around 400 million tests distributed globally by 2020. This breakthrough in technology is increasing the demand for accurate and quick malaria diagnosis.

Furthermore, increased government activities and financing for malaria prevention and control are critical to propelling the malaria diagnostics industry. The World Health Organization’s Global Technical Strategy for Malaria 2016-2030 seeks to reduce malaria infections and fatalities by at least 90% by 2030, including major investments from governments and NGOs. Malaria control and elimination activities will get around $3.3 billion in funding by 2021, demonstrating a commitment to improving diagnostic skills.

What Challenges Are Faced by the Malaria Diagnostics Market?

One of the most significant issues is a lack of diagnostic equipment in rural and remote areas where malaria is most common. Many afflicted regions, particularly those in Sub-Saharan Africa and Southeast Asia, lack basic healthcare infrastructure, making new diagnostic technology challenging to implement. This prevents quick and accurate disease detection, which is critical for effective treatment and control efforts.

While rapid diagnostic tests (RDTs) and microscopy are widely used, more advanced diagnostics such as molecular tests (PCR-based) are often too costly for widespread use in low-income regions. The high cost of these tests, along with the need for skilled technicians and laboratory equipment, poses a barrier to their adoption, especially in endemic areas where healthcare budgets are already constrained.

Furthermore, the reliability of diagnostic tools, particularly RDTs, is compromised by factors such as varying levels of parasite density and the presence of non-falciparum malaria strains. False negatives and inconsistent results hinder effective treatment and disease management, leading to continued transmission. Additionally, the emergence of drug-resistant malaria strains adds complexity to diagnostics, as existing tools do not accurately detect these evolving strains, creating further challenges in controlling the disease.

Category-Wise Insights

What Factors are Attributed to the Dominance of Rapid Diagnostic Tests?

RDTs are simple to use and provide quick results without the need for sophisticated laboratory infrastructure. This makes them particularly valuable in malaria-endemic regions where access to healthcare facilities and diagnostic labs is limited. According to the World Health Organization (WHO), over 70% of suspected malaria cases globally were tested using RDTs in 2022, highlighting their widespread use in areas with limited resources.

Compared to other diagnostic methods like microscopy or polymerase chain reaction (PCR), RDTs are more affordable, making them accessible to low- and middle-income countries where malaria is prevalent. Governments and international health organizations often prefer RDTs because they enable large-scale screening and timely detection at a fraction of the cost, helping to curb the spread of the disease in vulnerable populations.

Furthermore, International health bodies, such as the WHO and the Global Fund to Fight AIDS, Tuberculosis, and Malaria, heavily promote the use of RDTs as part of their malaria control programs. These organizations have invested significantly in scaling up RDT deployment, further reinforcing the market dominance of these tests. The increasing number of awareness campaigns and funding initiatives dedicated to malaria elimination has helped accelerate the adoption of RDTs across malaria-endemic regions, driving their dominance in the diagnostics market.

Which End-user Segment is Identified as the Largest Market Shareholder?

The hospital segment is identified as the largest market shareholder in the Malaria Diagnostics Market. This is due to the high volume of malaria cases diagnosed and treated in these healthcare settings. Hospitals serve as primary points of care, especially in malaria-endemic regions, where patients often rely on these facilities for accurate diagnosis and immediate treatment. The availability of trained healthcare professionals, coupled with the infrastructure to perform both traditional and advanced diagnostic tests, contributes to this segment’s dominance.

Furthermore, hospitals are more likely to adopt various diagnostic methods, including Rapid Diagnostic Tests (RDTs), microscopy, and molecular diagnostics, ensuring comprehensive testing capabilities. This broader range of diagnostic tools, along with government and NGO support for malaria control initiatives, strengthens the position of this segment in the market.

Gain Access to Malaria Diagnostics Market Report Methodology

https://www.verifiedmarketresearch.com/select-licence/?rid=39428

Country/Region-wise Acumens

What are the Key Factors that Contribute to the Middle East and Africa’s Edge in the Market?

According to VMR Analyst, the African region is projected to dominate the malaria diagnostics market during the forecast period. The Middle East and Africa region, particularly sub-Saharan Africa, experiences the highest burden of malaria globally, driving the demand for diagnostic tools. According to the World Health Organization (WHO) 2022 Malaria Report, Africa accounted for approximately 95% of all malaria cases and 96% of malaria deaths worldwide in 2021. This overwhelming disease burden necessitates widespread adoption of malaria diagnostics, particularly Rapid Diagnostic Tests (RDTs), to enable timely detection and treatment.

Significant investments from governments and non-governmental organizations (NGOs) in malaria control and eradication efforts have spurred demand for diagnostics in the region. Programs such as The President’s Malaria Initiative (PMI) and the Global Fund have committed billions to malaria control in Africa. The Global Fund’s 2022 report highlighted that in 2021, more than 281 million RDTs were distributed in sub-Saharan Africa, underscoring the importance of diagnostics in malaria elimination strategies.

Furthermore, several countries in the Middle East and Africa are actively working towards improving healthcare infrastructure and access, including malaria diagnostics. According to World Bank data, healthcare spending in sub-Saharan Africa increased by 7.4% annually between 2016 and 2020, reflecting a strong push toward universal healthcare access. This increased investment is driving the availability of malaria diagnostic services in rural and underserved areas, contributing to market growth in the region.

How Do Government Initiatives Shape the Market Landscape in the Asia Pacific?

The Asia Pacific region is estimated to exhibit the highest growth within the malaria diagnostics market during the forecast period. The Asia-Pacific region, particularly Southeast Asia, continues to report a significant number of malaria cases, driving the demand for diagnostic solutions. According to the World Health Organization (WHO) 2022 Malaria Report, the region accounted for 2% of global malaria cases in 2021, with countries like India, Myanmar, and Indonesia being among the most affected. This persistent disease burden has led to the widespread adoption of Rapid Diagnostic Tests (RDTs) and other diagnostic methods to control the spread of malaria in the region.

Countries in the Asia-Pacific region have launched aggressive campaigns to eliminate malaria, boosting demand for diagnostic tools. For instance, India’s National Framework for Malaria Elimination (NFME) 2016-2030 aims to achieve malaria-free status by 2030. According to the Indian Ministry of Health, the country saw a 66% decline in malaria cases between 2018 and 2022, largely due to increased diagnostic testing and treatment efforts. Such initiatives are pivotal in driving the demand for malaria diagnostics across the region.

Furthermore, the improvement of healthcare systems in Asia-Pacific, particularly in countries like China, India, and Vietnam, is contributing to greater access to malaria diagnostics. The Asian Development Bank (ADB) reported a 6.2% annual increase in healthcare spending across developing Asia-Pacific nations from 2015 to 2020. This expansion has allowed for the deployment of advanced diagnostic technologies and services, especially in rural areas where malaria remains endemic, further fueling market growth in the region.

Competitive Landscape

The competitive landscape of the malaria diagnostics market is characterized as diverse and dynamic. Various players are involved in the development and distribution of diagnostic solutions.

Some of the prominent players operating in the malaria diagnostics market include:

• Abbott Laboratories
• Bio-Rad Laboratories, Inc.
• Siemens Healthineers
• Beckman Coulter, Inc.
• Olympus Corporation
• Access Bio, Inc.
• Premier Medical Corporation Pvt. Ltd.
• Sysmex Corporation
• Leica Microsystems GmbH
• Novartis AG

Latest Developments

• In March 2022, Abbott launched a new malaria rapid diagnostic test (RDT) designed to detect Plasmodium vivax, a strain of malaria common in Asia and Latin America. The test is expected to enhance early detection of this specific strain, contributing to more effective malaria management in regions where P. vivax is prevalent.
• In October 2021, Access Bio, a leading diagnostic company, announced a partnership with the Global Fund to supply over 100 million rapid diagnostic tests (RDTs) across sub-Saharan Africa. This initiative aims to expand access to accurate and affordable malaria diagnostics, helping to combat the high malaria burden in the region.

Report Scope

Malaria Diagnostics Market, By Category

Test Type

• Clinical Chemistry
• Medical Microbiology & Cytology
• Human & Tumor Genetics
• Rapid Diagnostic Tests (RDTs)

Type of Lab

• Clinic-based
• Hospital-based
• Stand-alone

Region:

• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

Research Methodology of Verified Market Research:

To know more about the Research Methodology and other aspects of the research study, kindly get in touch with our Sales Team At Verified Market Research.

Reasons to Purchase this Report

• Qualitative and quantitative analysis of the market based on segmentation involving both economic as well as non-economic factors
• Provision of market value (USD Billion) data for each segment and sub-segment
• Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
• Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
• Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions and acquisitions in the past five years of companies profiled
• Extensive company profiles comprising of company overview, company insights, product benchmarking and SWOT analysis for the major market players
• The current as well as a future market outlook of the industry with respect to recent developments (which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
• Includes in-depth analysis of the market of various perspectives through Porter’s five forces analysis
• Provides insight into the market through Value Chain
• Market dynamics scenario, along with growth opportunities of the market in the years to come
• 6-month post-sales analyst support

Customization of the Report

• In case of any Queries or Customization Requirements please connect with our sales team, who will ensure that your requirements are met.